These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24879499)

  • 1. Insulin resistance, metabolic syndrome and chronic low grade inflammation in Sheehan's syndrome on standard replacement therapy: a case control study.
    Bhat MA; Laway BA; Shah ZA; Wani AI; Mubarik I
    Pituitary; 2015 Jun; 18(3):312-8. PubMed ID: 24879499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome.
    Tanriverdi F; Unluhizarci K; Kula M; Guven M; Bayram F; Kelestimur F
    Growth Horm IGF Res; 2005 Jun; 15(3):231-7. PubMed ID: 15921942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sheehan's syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer International Metabolic Database.
    Kelestimur F; Jonsson P; Molvalilar S; Gomez JM; Auernhammer CJ; Colak R; Koltowska-Häggström M; Goth MI
    Eur J Endocrinol; 2005 Apr; 152(4):581-7. PubMed ID: 15817914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency.
    Deepak D; Daousi C; Javadpour M; Clark D; Perry Y; Pinkney J; Macfarlane IA
    Growth Horm IGF Res; 2010 Jun; 20(3):220-5. PubMed ID: 20185347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of P300 auditory event related potential latency in detecting cognitive dysfunction in growth hormone (GH) deficient patients with Sheehan's syndrome and effects of GH replacement therapy.
    Golgeli A; Tanriverdi F; Suer C; Gokce C; Ozesmi C; Bayram F; Kelestimur F
    Eur J Endocrinol; 2004 Feb; 150(2):153-9. PubMed ID: 14763913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central hypothyroidism and its replacement have a significant influence on cardiovascular risk factors in adult hypopituitary patients.
    Klose M; Marina D; Hartoft-Nielsen ML; Klefter O; Gavan V; Hilsted L; Rasmussen AK; Feldt-Rasmussen U
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3802-10. PubMed ID: 23796569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two years of growth hormone replacement therapy in a group of patients with Sheehan's syndrome.
    Soares DV; Spina LD; de Lima Oliveira Brasil RR; Lobo PM; Salles E; Coeli CM; Conceição FL; Vaisman M
    Pituitary; 2006; 9(2):127-35. PubMed ID: 16944044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the skin characteristics in patients with severe GH deficiency and the effects of 6 months of GH replacement therapy: a randomized placebo controlled study.
    Tanriverdi F; Borlu M; Atmaca H; Koc CA; Unluhizarci K; Utas S; Kelestimur F
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):579-85. PubMed ID: 17054457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors of cardiovascular disease in GH-deficient adults with hypopituitarism: a preliminary report.
    Bohdanowicz-Pawlak A; Szymczak J; Bladowska J; Bednarek-Tupikowska G; Bidzińska B; Milewicz A
    Med Sci Monit; 2006 Feb; 12(2):CR75-80. PubMed ID: 16449951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of hematological abnormalities in patients with Sheehan's syndrome: response to replacement of glucocorticoids and thyroxine.
    Laway BA; Mir SA; Bashir MI; Bhat JR; Samoon J; Zargar AH
    Pituitary; 2011 Mar; 14(1):39-43. PubMed ID: 20798990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of short-term therapy with recombinant human growth hormone (GH) on metabolic parameters and preclinical atherosclerotic markers in hypopituitary patients with growth hormone deficiency.
    Benedini S; Dalle Carbonare L; Albiger N; Scanarini M; Bilora F; Petrobelli F; Giannini S; Mantero F; Scaroni C
    Horm Metab Res; 2006 Jan; 38(1):16-21. PubMed ID: 16477535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis.
    Abs R; Feldt-Rasmussen U; Mattsson AF; Monson JP; Bengtsson BA; Góth MI; Wilton P; Koltowska-Häggström M
    Eur J Endocrinol; 2006 Jul; 155(1):79-90. PubMed ID: 16793953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A.
    Joaquin C; Aguilera E; Granada ML; Pastor MC; Salinas I; Alonso N; Sanmartí A
    Eur J Endocrinol; 2008 Apr; 158(4):483-90. PubMed ID: 18362295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated leptin concentrations in growth hormone-deficient hypopituitary adults.
    al-Shoumer KA; Anyaoku V; Richmond W; Johnston DG
    Clin Endocrinol (Oxf); 1997 Aug; 47(2):153-9. PubMed ID: 9302387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults.
    Feldt-Rasmussen U; Wilton P; Jonsson P; ;
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S51-8. PubMed ID: 15135778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between metabolic syndrome components, low-grade systemic inflammation and insulin resistance in non-diabetic Indonesian adolescent male.
    Mansyur MA; Bakri S; Patellongi IJ; Rahman IA
    Clin Nutr ESPEN; 2020 Feb; 35():69-74. PubMed ID: 31987123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased thyrotrophin levels and loss of the nocturnal thyrotrophin surge in Sheehan's syndrome.
    Abucham J; Castro V; Maccagnan P; Vieira JG
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):515-22. PubMed ID: 9425390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sleep architecture in Sheehan's syndrome before and 6 months after growth hormone replacement therapy.
    Ismailogullari S; Tanriverdi F; Kelestimur F; Aksu M
    Psychoneuroendocrinology; 2009 Feb; 34(2):212-219. PubMed ID: 18930599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased plasma cholesterol esterification and cholesteryl ester transfer in hypopituitary patients on glucocorticoid replacement therapy.
    Beentjes JA; van Tol A; Sluiter WJ; Dullaart RP
    Scand J Clin Lab Invest; 2000 May; 60(3):189-98. PubMed ID: 10885490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities.
    Abdu TA; Neary R; Elhadd TA; Akber M; Clayton RN
    Clin Endocrinol (Oxf); 2001 Aug; 55(2):209-16. PubMed ID: 11531927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.